Estimated reading time at 200 wpm: 10 minutes

The issue begins with the Summary of Product Characteristics (SmPC). That’s just the manufacturers raw data and licence specifications that few doctors ever read. For methylphenidate (MPD), the list of contraindications is extensive and spans multiple physiological systems. In the UK regulatory framework, this creates a “red line” established by the MHRA through the drug’s Marketing Authorisation. This article should be informative for psychiatrists, medical line managers and non-medical managers.

While clinicians often treat “off-label” prescribing as a routine occurrence, prescribing against a contraindication is a fundamentally different act. It is a decision to override a specific safety warning where the manufacturer has already determined that the risk of harm outweighs the potential benefit. This can happen in practice, but the time and effort required to robustly justify the exception is significant.

Crucially, the SmPC serves as an ultimate risk-management tool for the manufacturer. In the UK, these contraindications are harmonised across all brands (e.g., Ritalin, Concerta XL, Medikinet, Equasym) following a European-wide safety review. By categorising these conditions as absolute contraindications rather than mere cautions, the manufacturer defines the boundaries of their legal liability. When a doctor chooses to prescribe against these “red lines,” they are accepting a total transfer of risk. Once the prescriber steps outside the Marketing Authorisation, the burden of proving safety shifts from the manufacturer’s clinical trials to the individual doctor’s professional judgement. The manufacturer is essentially indemnified for the very harms they identified, leaving the clinician as the primary insurer of the patient’s safety – up the creek hopefully with the right paddle.

Doctor’s who are in doubt or disbelief – or think this is ‘scare-mongering worry-wortism’ – should consult their defence unions or insurers. Non-medical managers should consult CNST.

Contraindicated Condition vs. Contraindicated Symptom

A point of frequent clinical confusion is the distinction between a contraindicated condition and a contraindicated symptom. In the SmPC for MPD, “Schizophrenia” is listed as a contraindication. This refers to the condition (the diagnosis or history), not merely the presence of active psychotic symptoms.

• Symptom-based Contraindication: If a drug were only contraindicated in “active psychosis,” a clinician could arguably prescribe it once the symptoms had subsided.
• Condition-based Contraindication: Because the diagnosis itself is the contraindication, the drug remains contraindicated even when the patient is currently asymptomatic or “stable” on antipsychotics.

By prescribing MPD to a patient with a history of schizophrenia, the clinician is overriding a warning that covers the patient’s underlying vulnerability, not just their current state. Relying on the absence of active symptoms to justify the prescription does not negate the fact that the use remains outside the licence. For the purposes of “professional judgement” under Para 6, the clinician must be prepared to justify why the manufacturer’s warning regarding the vulnerability is inapplicable, which is a much higher evidentiary bar than simply noting the patient is currently well. Those who approach this in a slapdash manner or hope Bolam will save them, will have a surprise waiting for them. Why? Bolam is a defence – not a cart blanche.

The SmPC (Section 4.3) defines this vulnerability by listing a comprehensive range of psychiatric contraindications that apply to both current diagnosis and clinical history:

• Diagnosis or history of severe depression.
• Anorexia nervosa or anorexic disorders.
• Suicidal tendencies.
• Psychotic symptoms.
• Severe mood disorders.
• Mania.
• Schizophrenia.
• Psychopathic or borderline personality disorder.
• Diagnosis or history of severe and episodic (Type 1) Bipolar (affective) disorder (that is not well controlled).

Beyond Psychiatric Injury: The Full Spectrum of Risk

For a consultant psychiatrist, the risk is not confined to triggering a psychotic relapse. The SmPC for methylphenidate lists contraindications that involve cardiovascular, cerebrovascular, and endocrine systems.

• Cardiovascular and Cerebrovascular Hazard: MPD is contraindicated in patients with pre-existing disorders such as severe hypertension, heart failure, arterial occlusive disease, and a history of stroke or cerebral aneurysm.
• Endocrine and Ocular Risks: Conditions like hyperthyroidism, thyrotoxicosis, glaucoma, and phaeochromocytoma are also explicitly listed.

When a psychiatrist prescribes MPD, they are not merely managing a psychiatric profile; they are assuming responsibility for the patient’s entire physiological stability. If a patient with a history of severe depression and undiagnosed hypertension suffers a stroke or a hypertensive crisis while on MPD, the psychiatrist’s liability extends to these non-psychiatric injuries. The manufacturer has already flagged these systems as being at high risk; therefore, any failure to screen for or monitor these “red line” conditions before overriding a contraindication makes the resulting harm legally foreseeable.

The Shift in Duty of Care

When a clinician crosses this line, the legal and professional burden of proof shifts. Under the GMC 2024 guidance (Good Medical Practice, Para 6), the standards allow for departures, but with a significant caveat:

“The professional standards describe good practice, and not every departure from them will be considered serious. You must use your professional judgement to apply the standards to your day-to-day practice. If you do this, act in good faith and in the interests of patients, you will be able to explain and justify your decisions and actions.”

By ignoring the SmPC’s contraindication, the clinician can no longer rely on the manufacturer’s safety data. They are operating in an evidentiary “no-man’s land”. The “professional judgement” mentioned in Paragraph 6 becomes the only shield. If that judgement cannot be backed by a documented, logical rationale that specifically addresses the manufacturer’s warning, the clinician is vulnerable.

From Clinical Relapse to Psychiatric Injury

A critical misunderstanding among some clinicians is the distinction between a natural relapse of a pre-existing condition and a psychiatric injury caused by medical intervention.

In a legal context, if a drug that is explicitly contraindicated for schizophrenia is prescribed and subsequently triggers a psychotic episode, that episode is categorised as an injury. The Montgomery (2015) precedent reinforces this; since the risk of relapse was a “material risk” explicitly identified by the manufacturer, the failure to protect the patient from that specific outcome—or the failure to ensure the patient fully understood and accepted that specific hazard—transforms a clinical setback into a compensable injury.

The Consent and Capacity Trap

The GMC 2024 Decision Making and Consent standards create a procedural requirement that is difficult to satisfy in this scenario.

1. Material Risk: The clinician must disclose “material risks”. Argue withe UK Supreme Court, if you wish. In this scenario, the risk is not just a side effect; it is the specific hazard warned of by the manufacturer.
2. Meaningful Dialogue: The doctor must document demonstration that the patient understands they are taking a medication that the manufacturer says they should not normally be taking in the particular circumstances.
3. Capacity Assessment: In a patient with schizophrenia, the capacity to “weigh up” the risk of a future psychotic episode against the immediate benefit of ADHD relief is a high-level cognitive task. If a formal, decision-specific capacity assessment is not documented at the point of prescription, the doctor has no defence if the warned-of harm occurs. But some doctors are willing to play dice because the CQC doesn’t know what’s what and the GMC does not check (even randomly) standards of medical practice.

Compounding Risk: Prison and “In-Possession” (IP)

In prison settings, the introduction of “automaticity” regarding in-possession medication further heightens the risk.

• The Stockpile Hazard: Methylphenidate is a Schedule 2 Controlled Drug. Giving a week or month’s supply to a patient with a history of mental instability or psychosis contradicts the basic principles of risk mitigation.
• The Failure of Monitoring: If a patient is “in-possession” of a contraindicated medication, the clinician has removed the very supervision (daily “see-to-take” observation) that might detect the early signs of the psychotic relapse the SmPC warns about.
• Regulatory Breach: Defaulting to IP for such a complex case ignores the GMC 2024 (Para 45) suggestion to work with pharmacists to avoid “overloading or confusing patients” and ensuring the delivery of medicine is safe within the specific environment.

Systemic Accountability: The Managerial Duty

The assumption that the risks associated with contraindicated prescribing are solely the concern of the individual clinician is a significant governance blind spot. Clinical and non-clinical managers share a structural responsibility for the safety of these practices.

When an organisation operates on “automaticity”—such as defaulting to “in-possession” (IP) medication in a prison or under-resourced clinic without individualised risk assessments—it is a failure of leadership as much as a failure of prescribing. Managers define the Standard Operating Procedures (SOPs). If those procedures do not mandate checks against SmPC contraindications, documented capacity assessments, or specialist pharmacist consultations (as suggested by Para 45), the organisation has created a system where clinicians are invited to bypass safety rails. Non-clinical managers, in particular, must recognise that overriding a contraindication is a high-resource exception that requires more MDT time and closer monitoring. Without this managerial awareness, the service operates in a high-risk “no-man’s land” where corporate liability is high and patient safety is compromised by procedural shortcuts.

The Myth of “Permissive” Guidance

Clinicians looking for a “permissive” alternative in NICE guidelines (NG87) will find that the document is largely silent on the specific issue of overriding absolute contraindications. While NG87 discusses clinical evidence for stimulants in adults, it does not provide a regulatory safety net or a framework for navigating the “red lines” of the SmPC.

This absence of guidance is significant. In the absence of a specific NICE-sanctioned protocol for prescribing against contraindications, the clinician is left solely with the GMC’s general requirements for off-label use.

There is often a confusion between clinical evidence and regulatory guidance. Recent cohort studies (e.g. from Sweden in 2024/25) may suggest that stimulants are relatively safe or even protective in schizophrenia when used with antipsychotics. However, a research paper is not a safety net. In a courtroom or at the GMC’s MPTS, a research study serves as a clinical rationale for taking a risk, but it does not move the regulatory “red line” of the SmPC. The clinician is still overriding a manufacturer’s absolute warning, and as such, the procedural requirements of Para 6 and Montgomery remain the only legal “paddles” available.

Conclusion of the Risk Chain

A clinician prescribing MPD to a patient with schizophrenia, and then allowing that medication to be held “in-possession” in a prison, has bypassed multiple safety rails:

1. The MHRA’s safety warning (the contraindication).
2. The GMC’s requirement for a documented, personalised safety justification (Para 6).
3. The Mental Capacity Act’s requirement for a specific assessment of the patient’s ability to handle a high-risk “hazard”.
4. The Prison Healthcare standards for robust In-Possession Risk Assessments (IPRA).

The reality is that while this path is open to clinicians, the labour required to pave it—through MDT consultation, rigorous capacity testing, and constant monitoring—is often missing in fast-paced or under-resourced environments. If harm occurs, the clinician is left defending a series of deviations from established professional guidance without the protection of a documented, compliant clinical process.

Supplemental reading list:

1. GMC Prescribing Standards
2. GMC standards on capacity/consent
3. NHS England on Methylphenidate
4. SmPC Methylphenidate
5. NICE NG87